Pilot Trial of the NK1 Receptor Radio-Ligand [18F]SPA-RQ: Imaging Pancreatic Ductal Adenocarcinoma
- Determine whether [18F]-labeled substance P antagonist receptor quantifier positron
emission tomography can identify pancreatic cancer evident on multiphase CT scan.
OUTLINE: Patients undergo multiphase CT scan of the chest, abdomen, and pelvis. No more than
15 days later, patients receive [18F]-labeled substance P antagonist receptor quantifier IV
and undergo positron emission tomography over 6 hours.
Blood is collected periodically to measure the metabolism of the radiotracer by high
performance liquid chromatography with radioactive detectors.
Allocation: Non-Randomized, Primary Purpose: Diagnostic
Proportion of tumors detected by [18F]-labeled substance P antagonist receptor quantifier positron emission tomography
Richard E. Royal, MD, FACS
NCI - Surgery Branch
United States: Food and Drug Administration
|Warren Grant Magnuson Clinical Center - NCI Clinical Trials Referral Office||Bethesda, Maryland 20892-1182|